{
    "nctId": "NCT00963417",
    "briefTitle": "Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02",
    "officialTitle": "TEXT-Bone: A Substudy of the TEXT Trial to Evaluate Serial Bone Markers for Bone Remodeling, Serial Growth Factors, and Bone Mineral Density",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Breast Cancer, Osteoporosis",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 119,
    "primaryOutcomeMeasure": "Serial serum levels of C-telopeptide, osteocalcin, and bone-specific alkaline phosphatase",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Patient must be eligible and enrolled in the TEXT-2 trial prior to enrolling in TEXT-Bone\n* Serial bone marrow density (BMD) measurements must be taken within the same institution\n* Hormone receptor positive\n\nPATIENT CHARACTERISTICS:\n\n* See Disease Characteristics\n* Premenopausal\n* No bone fracture in the past 6 months that, in the investigator's judgement, could be related to bone fragility\n* No clinical or biochemical malabsorption syndrome, known vitamin D deficiency, active hyper- or hypoparathyroidism, or Paget's disease\n* No uncontrolled thyroid disease, Cushing disease, or other pituitary diseases\n* No other bone disease (including osteomalacia or osteogenesis imperfecta)\n\nPRIOR CONCURRENT THERAPY:\n\n* See Disease Characteristics\n* At least 6 months since prior and no concurrent bisphosphonate therapy (or other bone therapies such as PTH or strontium)\n* At least 6 months since prior glucocorticoid (\\> 5 mg prednisone or equivalent) for \\> 1 month\n* At least 12 months since prior anticonvulsants",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}